| |
|
Form Serial Number: |
DA20250519E00384
|
| 1.
Date of relevant event: |
14/05/2025
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
01541 |
| 4.
Name of listed corporation: |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. - B - H Shares |
| 5.
Class of shares: |
H Shares |
| 6.
Number of issued shares in class: |
396,277,305 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Tian |
| (Other names) |
Wenzhi |
|
|
|
| 10.
Name of director (Chinese): |
田文志 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1711 | Miscellaneous
Other (you must briefly describe the relevant event in the Supplementary Information box) |
|
| 2501 | Other (you must describe the capacity in the Supplementary Information box) |
|
| 2501 | Other (you must describe the capacity in the Supplementary Information box) |
|
|
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 116,034,090 | 30.36 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 116,034,090 | 29.28 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| |
| 2201 | Interest of corporation controlled by you |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| Spouse | Ms. Yumei Ding | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| Jiaxing Hanning Enterprise Management Co., Ltd. (嘉興翰濘企業管理有限公司) | Room 170-48, Building 1, Fund Town, 1856 Nanjiang Road, Dongzha Street, Nanhu District, Jiaxing City, Zhejiang Province (PRC) | Tian Wenzhi | 99.00 | N | |
| Jiaxing Changyu Enterprise Management L.P. (Limited Partnership) (嘉興昶宇企業管理合夥企業(有限合夥)) | Room 170-8, Building 1, Fund Town, 1856 Nanjiang Road, Dongzha Street, Nanhu District, Jiaxing City, Zhejiang Province (PRC) | Jiaxing Hanning Enterprise Management Co., Ltd. (嘉興翰濘企業管理有限公司) | 100.00 | Y | |
| Jiaxing Changxian Enterprise Management L.P. (Limited Partnership) (嘉興昶咸企業管理合夥企業(有限合夥)) | Room 170-47, Building 1, Fund Town, 1856 Nanjiang Road, Dongzha Street, Nanhu District, Jiaxing City, Zhejiang Province (PRC) | Jiaxing Hanning Enterprise Management Co., Ltd. (嘉興翰濘企業管理有限公司) | 100.00 | Y | |
| Halo Biomedical Investment I Limited | Commerce House, Wickhams Cay 1, P.O. Box 3140, Road Town, Tortola, British Virgin Islands VG1110 (British Virgin Islands) | Tian Wenzhi | 100.00 | N | |
| Halo Biomedical LP | Commerce House, Wickhams Cay 1, P.O. Box 3140, Road Town, Tortola, British Virgin Islands VG1110 (British Virgin Islands) | Halo Biomedical Investment I Limited | 100.00 | N | |
| Halo Biomedical Investment II Limited | Commerce House, Wickhams Cay 1, P.O. Box 3140, Road Town, Tortola, British Virgin Islands VG1110 (British Virgin Islands) | Halo Biomedical LP | 100.00 | Y | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
Box24: the Company has completed H share full circulation on May 14, 2025 where 14,114,006 unlisted shares have been converted into H shares. See announcement dated May 14, 2025. Box30: Dr. Tian controlled all of Halo Investment I's voting rights. Dr. Yumei Ding, the spouse of Dr. Tian holds approximately 73.79% limited partnership interests in Halo LP (among which 54.19% limited partnership interests were held on behalf of Dr. Tian by Dr. Ding). See Company's prospectus.
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
19/05/2025
(dd/mm/yyyy)
|
| |